These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 22791906)

  • 1. Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
    Zajicek JP; Hobart JC; Slade A; Barnes D; Mattison PG;
    J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1125-32. PubMed ID: 22791906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Killestein J; Hoogervorst EL; Reif M; Kalkers NF; Van Loenen AC; Staats PG; Gorter RW; Uitdehaag BM; Polman CH
    Neurology; 2002 May; 58(9):1404-7. PubMed ID: 12011290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Zajicek J; Fox P; Sanders H; Wright D; Vickery J; Nunn A; Thompson A;
    Lancet; 2003 Nov; 362(9395):1517-26. PubMed ID: 14615106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT; Makela P; Robson P; House H; Bateman C
    Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.
    Zajicek JP; Sanders HP; Wright DE; Vickery PJ; Ingram WM; Reilly SM; Nunn AJ; Teare LJ; Fox PJ; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1664-9. PubMed ID: 16291891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB
    Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract]   [Full Text] [Related]  

  • 10. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
    Wade DT; Robson P; House H; Makela P; Aram J
    Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
    Serpell MG; Notcutt W; Collin C
    J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ; Nurmikko TJ; Friede T; Young CA
    Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
    Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicinal cannabis extracts for the treatment of multiple sclerosis.
    Smith PF
    Curr Opin Investig Drugs; 2004 Jul; 5(7):727-30. PubMed ID: 15298068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.
    Wright S; Duncombe P; Altman DG
    Trials; 2012 Oct; 13():189. PubMed ID: 23046749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.